Bone Graft Substitutes Market Size, Share, Growth Analysis, By Material Type(Allograft (Demineralized Bone Matrix and Others) and Synthetic (Ceramics, Composites, Polymers, Bone Morphogenic Proteins)), By Application(Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction), By Region - Industry Forecast 2024-2031

In May 2024, Irvine-based Biogennix, LLC, an osteobiologics company, has announced the receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications of its Agilon Moldable and Morpheus Moldable bone grafting products. 

In Jan 2024, Cerapedics Inc., an orthopedics company at the forefront of bone repair innovation, has announced the submission of the final module in their Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the P-15 Peptide Enhanced Bone Graft. This submission marks a significant milestone for Cerapedics, as it could lead to the approval of their second Class III drug/device combination product designed for lumbar spine fusion with a TLIF indication. 

In October 2023, Orthofix Medical Inc. (NASDAQ:OFIX), a global leader in spine and orthopedics, has announced the 510k clearance and full commercial launch of OsteoCove™, a cutting-edge bioactive synthetic graft. 

In May 2023, Zimmer Biomet Holdings, Inc. announced the launch of its VIVIX 3D Printed Bone Matrix, a breakthrough bone graft substitute with a porous structure designed to mimic the natural bone environment. 

In April 2023, Stryker Corporation acquired NuVasive, Inc., a leading provider of spine surgery solutions, expanding its product portfolio in the bone graft substitutes market and strengthening its presence in the spine care segment. 

In February 2023, Osseus Fusion Systems received FDA clearance for its ARIES-TS spinal implant system, designed for use with autograft or bone graft substitutes in posterior lumbar interbody fusion (PLIF) surgeries. 

In December 2022, Kuros Biosciences announced a collaboration with Johnson & Johnson Medical Devices Companies to co-develop innovative orthobiologic solutions for bone graft substitutes and regenerative medicine. 

In September 2022, SeaSpine Holdings Corporation launched the Mariner MIS Posterior Fixation System, an innovative platform that combines pedicle screw fixation and bone grafting options for minimally invasive spinal fusion procedures.